Advertisement
U.S. markets open in 56 minutes
  • S&P Futures

    5,307.00
    -1.25 (-0.02%)
     
  • Dow Futures

    40,159.00
    +15.00 (+0.04%)
     
  • Nasdaq Futures

    18,500.50
    -3.25 (-0.02%)
     
  • Russell 2000 Futures

    2,140.00
    +1.60 (+0.07%)
     
  • Crude Oil

    82.62
    +1.27 (+1.56%)
     
  • Gold

    2,232.20
    +19.50 (+0.88%)
     
  • Silver

    24.69
    -0.06 (-0.25%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2623
    -0.0015 (-0.12%)
     
  • USD/JPY

    151.3530
    +0.1070 (+0.07%)
     
  • Bitcoin USD

    70,396.20
    +154.44 (+0.22%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.37
    +20.39 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

(Reuters) - AstraZeneca's (AZN.L) first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.

Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.

(Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman)

Advertisement